Do perfluoroalkyl substances affect metabolic function and plasma lipids?-Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1

Environmental Research

Volumn 121, Issue , 2013, Pages 95-103

  Fisher, Mandy ^a   Arbuckle, Tye E ^a   Wade, Mike ^a   Haines, Douglas A ^a  

^a HEALTH CANADA   (Canada)

Author keywords

Biomonitoring; Cholesterol; Epidemiology; Metabolic syndrome; Metabolism; Perfluorinated compounds

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERFLUORO COMPOUND; PERFLUOROHEXANE SULFONATE; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; UNCLASSIFIED DRUG;

ANIMAL; AQUATIC ENVIRONMENT; BIOMONITORING; EPIDEMIOLOGY; GLOBAL PERSPECTIVE; HEALTH RISK; HEALTH SURVEY; HOMEOSTASIS; METABOLISM; PLASMA; PUBLIC HEALTH; SAMPLING; SPATIOTEMPORAL ANALYSIS;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; METABOLISM; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALKANESULFONIC ACIDS; CANADA; CAPRYLATES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; GLUCOSE; HEALTH SURVEYS; HOMEOSTASIS; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; SULFONIC ACIDS; YOUNG ADULT;

ANIMALIA;

EID: 84873992035     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2012.11.006     Document Type: Article

References (72)

1. Ahrens L. Polyfluoroalkyl compounds in the aquatic environment: a review of their occurrence and fate. J. Environ. Monit. 2011, 13:20-31.
2. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
3. Bijland S., Rensen P.C., Pieterman E.J., Maas A.C., van der Hoorn J.W., van Erk M.J., Havekes L.M., Willems van Dijk K., Chang S.C., Ehresman D.J., Butenhoff J.L., Princen H.M. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicol. Sci. 2011, 123:290-303.
4. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288:8-17.
5. Butenhoff J.L., Bjork J.A., Chang S.C., Ehresman D.J., Parker G.A., Das K., Lau C., Lieder P.H., van Otterdijk F.M., Wallace K.B. Toxicological evaluation of ammonium perfluorobutyrate in rats: twenty-eight-day and ninety-day oral gavage studies. Reprod. Toxicol. 2012, 33:513-530.
6. Butt C.M., Berger U., Bossi R., Tomy G.T. Levels and trends of poly- and perfluorinated compounds in the arctic environment. Sci. Total Environ. 2010, 408:2936-2965.
7. Calafat A.M., Wong L.Y., Kuklenyik Z., Reidy J.A., Needham L.L. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ. Health Perspect. 2007, 115:1596-1602.
8. Canadian Heart & Stroke Foundation. 2010. Living with Cholesterol: Cholesterol and Healthy Living. Heart and Stroke Foundation of Canada.
9. Centers for Disease Control. 2009. Fourth National Report on Human Exposure to Environmental Chemicals. (Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Georgia).
10. Chateau-Degat M.L., Pereg D., Dallaire R., Ayotte P., Dery S., Dewailly E. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ. Res. 2010, 110:710-717.
11. Clarke D.B., Bailey V.A., Routledge A., Lloyd A.S., Hird S., Mortimer D.N., Gem M. Dietary intake estimate for perfluorooctanesulphonic acid (PFOS) and other perfluorocompounds (PFCs) in UK retail foods following determination using standard addition LC-MS/MS. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess 2010, 27:530-545.
12. Conder J.M., Hoke R.A., De W.W., Russell M.H., Buck R.C. Are PFCAs bioaccumulative? A critical review and comparison with regulatory criteria and persistent lipophilic compounds. Environ. Sci. Technol. 2008, 42:995-1003.
13. Costa G., Sartori S., Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. J. Occup. Environ. Med. 2009, 51:364-372.
14. Craig S.R., Amin R.V., Russell D.W., Paradise N.F Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J. Gen. Intern. Med. 2000, 15:395-399.
15. D'eon J.C., Mabury S.A. Exploring indirect sources of human exposure to perfluoroalkyl carboxylates (PFCAs): evaluating uptake, elimination, and biotransformation of polyfluoroalkyl phosphate esters (PAPs) in the rat. Environ. Health Perspect. 2011, 119:344-350.
16. D'eon J.C., Mabury.S.A. Is indirect exposure a significant contributor to the burden of perfluorinated acids observed in humans?. Environ. Sci. Technol. 2011, 45:7974-7984.
17. D'Hollander W., de V.P., De C.W., Bervoets L. Perfluorinated substances in human food and other sources of human exposure. Rev. Environ. Contam. Toxicol. 2010, 208:179-215.
18. Egeghy P.P., Lorber M. An assessment of the exposure of Americans to perfluorooctane sulfonate: a comparison of estimated intake with values inferred from NHANES data. J. Expo. Sci. Environ. Epidemiol 2010.
19. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. Toxicology 2012, 293:16-29.
20. Elcombe C.R., Elcombe B.M., Foster J.R., Farrar D.G., Jung R., Chang S.C., Kennedy G.L., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. Arch. Toxicol. 2010, 84:787-798.
21. Emmett EA, Zhang H., Shofer F.S., Freeman D., Rodway N.V., Desai C., Shaw L.M. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 2006, 48:771-779.
22. EPA. 2012. 2010/2015 PFOA Stewardship Program. Environmental Protection Agency. (accessed June 19, 2012). http://www.epa.gov/oppt/pfoa/pubs/pfoainfo.html.
23. Frisbee S.J., Shankar A., Knox S.S., Steenland K., Savitz D.A., Fletcher T., Ducatman AM. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch. Pediatr. Adolesc. Med. 2010, 164:860-869.
24. Fromme H., Tittlemier S.A., Volkel W., Wilhelm M., Twardella D. Perfluorinated compounds-exposure assessment for the general population in Western countries. Int. J. Hyg. Environ. Health 2009, 212:239-270.
25. Giesy J.P., Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci. Technol. 2001, 35:1339-1342.
26. Giroux S. 2006. Sample design of the Canadian Health Measures Survey. Proceedings of Statistics Canada's Symposium 2006: Methodolgoical Issues in Measuring Population Health. Statistics Canada. Catalogue no. 11-522-XIE.
27. Glynn A., Berger U., Bignert A., Ullah S., Aune M., Lignell S., Darnerud P.O. Perfluorinated alkyl acids in blood serum from primiparous women in Sweden: serial sampling during pregnancy and nursing, and temporal trends 1996-2010. Environ. Sci. Technol. 2012, 46:9071-9079.
28. Greenland S., Rothman R. 1998. Introduction to categorical statistics. In: Modern Epidemiology. Lippincott-Raven Publications, Philadelphia, PApp. 231-279.
29. Grimes D.A., Schulz K. Bias and causal associations in observational research. Lancet 2002, 359:248-252.
30. Haughom B., Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta. 1992, 1128:65-72.
31. Health Canada. 2010. Report on Human Biomonitoring of Environmental Chemicals in Canada: Results of the Canadian Health Measures Survey Cycle 1 (2007-2009). Health Canada, Ottawa, Ontario.
32. INSPQ. 2009. Analytical Method for the Determination of Perfluroinated Compounds (PFCs) in Plasma by HPLC-MS-MS (E-434), condensed version. Laboratoire de toxicologie, Institut national de santé publique du Québec.
33. Karrman A., Domingo J.L., Llebaria X., Nadal M., Bigas E, van B.B., Lindstrom G. Biomonitoring perfluorinated compounds in Catalonia, Spain: concentrations and trends in human liver and milk samples. Environ. Sci. Pollut. Res. Int. 2010, 17:750-758.
34. Kato K., Wong L.Y., Jia L.T., Kuklenyik Z., Calafat A.M. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population:1999-2008. Environ. Sci. Technol. 2011, 45:8037-8045.
35. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp.P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
36. Korn E.L., Graubard B.I. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am. J. Public Health. 1991, 81:1166-1173.
37. Kudo N., Kawashima Y. Induction of triglyceride accumulation in the liver of rats by perfluorinated fatty acids with different carbon chain lengths: comparison with induction of peroxisomal beta-oxidation. Biol. Pharm. Bull. 2003, 26:47-51.
38. Lang I.A., Galloway T.S., Scarlett A., Henley W.E., Depledge M., Wallace R.B., Melzer D. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008, 300:1303-1310.
39. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 2007, 99:366-394.
40. Li J., Del V.S., Schuster J., Zhang G., Chakraborty P., Kobara Y., Jones K.C. Perfluorinated compounds in the Asian atmosphere. Environ. Sci. Technol. 2011, 45:7241-7248.
41. Lin C.Y., Chen P.C., Lin Y.C., Lin L.Y. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care 2009, 32:702-707.
42. Lin C.Y., Lin L.Y., Chiang C.K., Wang W.J., Su Y.N., Hung K.Y., Chen P.C. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am. J. Gastroenterol. 2010, 105:1354-1363.
43. Llorca M., Farre M., Pico Y., Teijon M.L., Alvarez J.G., Barcelo D. Infant exposure of perfluorinated compounds: levels in breast milk and commercial baby food. Environ. Int. 2010, 36:584-592.
44. Mak Y.L., Taniyasu S., Yeung L.W., Lu G., Jin L., Yang Y., Lam P.K., Kannan K., Yamashita N. Perfluorinated compounds in tap water from China and several other countries. Environ. Sci. Technol. 2009, 43:4824-4829.
45. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
46. Meeker J.D., Ferguson K.K. Relationship between urinary phthalate and bisphenol A concentrations and serum thyroid measures in U.S. adults and adolescents from the National Health and Nutrition Examination Survey (NHANES) 2007-2008. Environ. Health Perspect. 2011, 119:1396-1402.
47. Melzer D., Rice N.E., Lewis C., Henley W.E., Galloway T.S. Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06. PLoS One 2010, 5:e8673.
48. Mora S., Rifai N., Buring J.E., Ridker P.M. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118:993-1001.
49. Nelson J.W., Hatch E.E., Webster T.F. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ. Health Perspect. 2010, 118:197-202.
50. Olsen G.W., Lange C.C., Ellefson M.E., Mair D.C., Church T.R., Goldberg C.L., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., Rios J.A., Reagen W.K., Zobel L.R. Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000-2010. Environ. Sci. Technol. 2012, 46:6330-6338.
51. Olsen G.W., Burris J.M., Burlew M.M., Mandel J.H. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 2003, 45:260-270.
52. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
53. Olsen G.W., Burris J.M., Mandel J.H., Zobel L.R. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J. Occup. Environ. Med. 1999, 41:799-806.
54. Quinones O., Snyder S.A. Occurrence of perfluoroalkyl carboxylates and sulfonates in drinking water utilities and related waters from the United States. Environ. Sci. Technol. 2009, 43:9089-9095.
55. Ren H., Vallanat B., Nelson D.M., Yeung L.W., Guruge K.S., Lam P.K., Lehman-McKeeman L.D., Corton J.C. Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod. Toxicol. 2009, 27:266-277.
56. Rosen M.B., Abbott B.D., Wolf D.C., Corton J.C., Wood C.R., Schmid J.E., Das K.P., Zehr R.D., Blair E.T., Lau C. Gene profiling in the livers of wild-type and PPARalpha-null mice exposed to perfluorooctanoic acid. Toxicol. Pathol. 2008, 36:592-607.
57. Rosen M.B., Lee J.S., Ren H., Vallanat B., Liu J., Waalkes M.P., Abbott B.D., Lau C., Corton J.C. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. Toxicol. Sci. 2008, 103:46-56.
58. Sakr C.J., Kreckmann K.H., Green J.W., Gillies P.J., Reynolds J.L., Leonard R.C. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J. Occup. Environ. Med. 2007, 49:1086-1096.
59. Sakr C.J., Leonard R.C., Kreckmann K.H., Slade M.D., Cullen M.R. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J. Occup. Environ. Med. 2007, 49:872-879.
60. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 2002, 68:249-264.
61. Statistics, Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 1. 2010.
62. Steenland K., Tinker S., Frisbee S., Ducatman A., Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am. J. Epidemiol. 2009, 170:1268-1278.
63. Statistics Canada. 2010. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 1. Catalogue No. 82-623-X.
64. Steenland K., Fletcher T., Savitz D.A. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 2010, 118:1100-1108.
65. Steenland K., Tinker S., Frisbee S., Ducatman A., Vaccarino V Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am. J. Epidemiol. 2009, 170:1268-1278.
66. Sundstrom M., Ehresman D.J., Bignert A., Butenhoff J.L., Olsen G.W., Chang S.C., Bergman A. A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. Environ. Int. 2011, 37:178-183.
67. Tremblay M., Wolfson M., Gorber S.C. Canadian Health Measures Survey: rationale, background and overview. Health Rep. 2007, (Suppl. 7-20):18.
68. Vacca M., Degirolamo C., Mariani-Costantini R., Palasciano G., Moschetta A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley. Interdiscip. Rev. Syst. Biol. Med 2011, 3:562-587.
69. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
70. Wang M., Park J.S., Petreas M. Temporal changes in the levels of perfluorinated compounds in California women's serum over the past 50 years. Environ. Sci. Technol. 2011, 45:7510-7516.
71. Wilder L.B., Bachorik P.S., Finney C.A., Moy T.F., Becker D.M. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am. J. Med. 1995, 99:374-377.
72. Wolf C.J., Takacs M.L., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol. Sci. 2008, 106:162-171.